The growth trajectory for the Indian pharmaceutical industry is likely to remain at 10-13 per cent in 2020-21 despite challenges, according to rating agency Icra. The expected growth in the next financial year is on the back of healthy demand from the domestic market given increasing spend on healthcare along with improving access, Icra said in a statement. This along with abatement in pricing pressure for the US market, new launches and market share gains for existing products and consolidation benefits will drive growth in 2020-21, it added. “The Indian pharmaceutical industry’s growth remained stable at 12.2 per cent during H1 FY2020 led by rebound in domestic growth in Q2 FY2020 to 14.2 per cent supported by seasonal factors and stable growth in chronic therapies,” Icra Vice President & Co-Head Gaurav Jain said.

(Economic Times)